Tiziana Life Sciences Shares Jump After Multiple Sclerosis Data From Second Patient

Tiziana Life Sciences TLSA reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program.
These results confirm the previously reported data from the first SPMS patient after three months of treatment of the first SPMS patient.
The treatment with foralumab, a fully human anti-CD3 monoclonal antibody, was well-tolerated and improved clinical and PET imaging analyses.
Related: Tiziana Life Shares Rise On Encouraging Data From Intranasal Foralumab In Multiple Sclerosis Patient.
After three months of treatment with intranasal foralumab, the patient showed improvement as measured by PET imaging and neurologic examination.
Approximately 10-30% reduction in PET signal was seen across brain regions in the second SPMS patient, comparable to the PET changes seen in the first SPMS patient.
Clinically, the Timed 25-Foot Walk test and neurologic exam were also improved.
The FDA has now allowed Tiziana to treat an additional eight SPMS patients.
Although the original dosing regimen with intranasal therapy with foralumab will remain the same (50 mcg), the revised regimen has a dose escalation of up to 100 mcg (MWF), an option to improve clinical benefit.
Price Action: TLSA shares are up 11.95% at $0.82 during the market session on the last check Wednesday.